Erratum: Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter(International Journal of Cancer (2013) 132:3 (509-520) 10.1002/ijc.27690);Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter

International Journal of Cancer

Volumn 132, Issue 3, 2013, Pages 509-520

  Latha, Khatri ^a   Li, Ming ^b   Chumbalkar, Vaibhav ^a   Gururaj, Anupama ^a   Hwang, Yeohyeon ^a   Dakeng, Sumana ^a   Sawaya, Raymond ^a   Aldape, Kenneth ^c   Cavenee, Webster K ^b   Bogler, Oliver ^a,c   Furnari, Frank B ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bcl XL; glioma transcriptional regulation; nuclear EGFRvIII EGFR; STAT5b

Indexed keywords

AURORA A KINASE; CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; PROTEIN BCL XL; STAT5B PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AURORA A GENE; BCL XL GENE; CELL NUCLEUS; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIZATION; EMBRYO; GENE; GENETIC REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84870239957     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29552     Document Type: Erratum

References (49)

1. Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987; 84: 6899-903.
2. Frederick L, Eley G, Wang XY, et al. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro Oncol 2000; 2: 159-63.
3. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89: 2965-9.
4. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63: 6962-70.
5. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11: 1462-6.
6. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007; 25: 2288-94.
7. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996; 56: 5079-86.
8. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91: 7727-31.
9. Chumbalkar V, Latha K, Hwang Y, et al. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of DeltaEGFR. J Proteome Res 2011; 10: 1343-52.
10. Liu X, Robinson GW, Gouilleux F, et al. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 1995; 92: 8831-5.
11. Coffer PJ, Koenderman L, de Groot RP,. The role of STATs in myeloid differentiation and leukemia. Oncogene 2000; 19: 2511-22.
12. Nevalainen MT, Xie J, Torhorst J, et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004; 22: 2053-60.
13. Li H, Ahonen TJ, Alanen K, et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 2004; 64: 4774-82.
14. Grimley PM, Dong F, Rui H,. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 1999; 10: 131-57.
15. Frasor J, Park K, Byers M, et al. Differential roles for signal transducers and activators of transcription 5a and 5b in PRL stimulation of ERalpha and ERbeta transcription. Mol Endocrinol 2001; 15: 2172-81.
16. Zeng R, Aoki Y, Yoshida M, et al. Stat5B shuttles between cytoplasm and nucleus in a cytokine-dependent and -independent manner. J Immunol 2002; 168: 4567-75.
17. Iyer J, Reich NC,. Constitutive nuclear import of latent and activated STAT5a by its coiled coil domain. FASEB J 2008; 22: 391-400.
18. Yamashita H, Xu J, Erwin RA, et al. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 1998; 273: 30218-24.
19. Iavnilovitch E, Cardiff RD, Groner B, et al. Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 2004; 112: 607-19.
20. Lee TK, Man K, Poon RT, et al. Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res 2006; 66: 9948-56.
21. Liang QC, Xiong H, Zhao ZW, et al. Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells. Cancer Lett 2009; 273: 164-71.
22. Nagane M, Levitzki A, Gazit A, et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 1998; 95: 5724-9.
23. Lo HW, Ali-Seyed M, Wu Y, et al. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 2006; 98: 1570-83.
24. Lo HW, Cao X, Zhu H, et al. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res 2010; 8: 232-45.
25. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-73.
26. Burton EC, Lamborn KR, Forsyth P, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002; 8: 180-7.
27. Hung LY, Tseng JT, Lee YC, et al. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res 2008; 36: 4337-51.
28. Quesnelle KM, Boehm AL, Grandis JR,. STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007; 102: 311-9.
29. Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998; 93: 841-50.
30. Wang YN, Yamaguchi H, Hsu JM, et al. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene 2010; 29: 3997-4006.
31. de la Iglesia N, Konopka G, Puram SV, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 2008; 22: 449-62.
32. Hsu SC, Hung MC,. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem 2007; 282: 10432-40.
33. Rane SG, Reddy EP,. Janus kinases: components of multiple signaling pathways. Oncogene 2000; 19: 5662-79.
34. Silva CM,. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017-23.
35. Ahluwalia MS, de Groot J, Liu WM, et al. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett 2010; 298: 139-49.
36. Araujo J, Logothetis C,. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 2010; 36: 492-500.
37. Verstovsek S, Manshouri T, Quintas-Cardama A, et al. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 2008; 14: 788-96.
38. Lu KV, Zhu S, Cvrljevic A, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res 2009; 69: 6889-98.
39. Kloth MT, Catling AD, Silva CM,. Novel activation of STAT5b in response to epidermal growth factor. J Biol Chem 2002; 277: 8693-701.
40. Turkson J,. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004; 8: 409-22.
41. Cao S, Wang C, Zheng Q, et al. STAT5 regulates glioma cell invasion by pathways dependent and independent of STAT5 DNA binding. Neurosci Lett 2011; 487: 228-33.
42. Fox EM, Bernaciak TM, Wen J, et al. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol 2008; 22: 1781-96.
43. Yang J, Stark GR,. Roles of unphosphorylated STATs in signaling. Cell Res 2008; 18: 443-51.
44. Iida M, Brand TM, Campbell DA, et al. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene 2012. Doi: 10.1038/onc.2012.90.
45. Chakravarti A, Dicker A, Mehta M,. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 2004; 58: 927-31.
46. Huang PH, Cavenee WK, Furnari FB, et al. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle 2007; 6: 2750-4.
47. Qian YH, Xiao Q, Chen H, et al. Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway. Biochim Biophys Acta 2009; 1793: 764-71.
48. Hsu SC, Miller SA, Wang Y, et al. Nuclear EGFR is required for cisplatin resistance and DNA repair. Am J Transl Res 2009; 1: 249-58.
49. Li C, Iida M, Dunn EF, et al. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28: 3801-13.